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Background: Solid tumors need new blood vessels to feed and nourish them as well as to 
allow tumor cells to escape into the circulation and lodge in other organs, which is termed 
“  angiogenesis.” Some tumor cells within solid tumors can overexpress integrins αvβ3 and αvβ5, 
which can specifically recognize the peptide motif Arg-Gly-Asp (RGD). Thus, the targeting 
of RGD-modified micelles to tumor vasculature is a promising strategy for tumor-targeting 
treatment.
Methods: RGD peptide (GSSSGRGDSPA) was coupled to poly(ethylene glycol)-modified 
stearic acid-grafted chitosan (PEG-CS-SA) micelles via chemical reaction in the presence of 
N,N′-Disuccinimidyl carbonate. The critical micelle concentration of the polymeric micelles 
was determined by measuring the fluorescence intensity of pyrene as a fluorescent probe. 
The micelle size, size distribution, and zeta potential were measured by light scattering and 
  electrophoretic mobility. Doxorubicin (DOX) was chosen as a model anticancer drug to 
investigate the drug entrapment efficiency, in vitro drug-release profile, and in vitro antitumor 
activities of drug-loaded RGD-PEG-CS-SA micelles in cells that overexpress integrins (ανβ3 
and ανβ5) and integrin-deficient cells.
Results: Using DOX as a model drug, the drug encapsulation efficiency could reach 90%, 
and the in vitro drug-release profiles suggested that the micelles could be used as a controlled-
release carrier for the hydrophobic drug. Qualitative and quantitative analysis of cellular uptake 
indicated that RGD-modified micelles could significantly increase the DOX concentration 
in integrin-overexpressing human hepatocellular carcinoma cell line (BEL-7402), but not in 
human epithelial carcinoma cell line (Hela). The competitive cellular-uptake test showed that 
the cellular uptake of RGD-modified micelles in BEL-7402 cells was significantly inhibited in 
the presence of excess free RGD peptides. In vitro cytotoxicity tests demonstrated DOX-loaded 
RGD-modified micelles could specifically enhance the cytotoxicity against BEL-7402 compared 
with DOX-loaded PEG-CS-SA and doxorubicin hydrochlorate.
Conclusion: This study suggests that RGD-modified PEG-CS-SA micelles are promising drug 
carriers for integrin-overexpressing tumor active targeting therapy.
Keywords: cellular uptake, chitosan polymeric micelles, cytotoxicity, doxorubicin, integrin, 
RGD peptide
Introduction
It is well-known that cancer cells are inherently more vulnerable to chemotherapy 
than the majority of normal cells, but most anticancer drugs are nonselective and can 
cause injury to normal tissues. In recent years, efforts have focused on effective and 
safe cancer therapy by increasing tumor targeting while sparing normal cells.1 It has 
successfully been demonstrated that polymers can form effective delivery systems 
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for anticancer drugs via an enhanced permeation and reten-
tion (EPR) effect, termed as “passive targeting.”2 Polymeric 
micelles as drug delivery systems (DDSs) were introduced 
in the early 1990s by Kataoka’s group through the develop-
ment of doxorubicin-conjugated block copolymer micelles.3 
They have also been used for the delivery of many anticancer 
agents in preclinical and clinical studies.4–6
However, since most clinical conditions do not allow pas-
sive targeting, active targeting, where the nanoparticles are 
delivered to the targets by specific ligands, becomes necessary. 
Active-targeted delivery of anticancer drugs is a promising 
approach for delivery of nanoparticle systems. Long circu-
lation times will allow effective transport of nanoparticles 
to the tumor site through the EPR effect, and the targeting 
molecule can increase endocytosis of the nanoparticles.7 
Polymeric micelles are the only reported DDS that conquers 
multiple-drug resistance through absolute targeting using 
various approaches such as passive targeting, folate-mediated 
DDSs, and pH-sensitive and thermosensitive DDSs.8
Chitosan (CS), a biodegradable, biocompatible polysac-
charide with low toxicity and immunity system induction,9 
has been widely accepted as a potential material for drug 
delivery carriers.10,11 Poly(ethylene glycol) (PEG) is a non-
toxic and nonirritant hydrophilic polymer.12 PEGylation is 
one of the most popular methods to overcome the uptake of 
polymeric micelles by macrophage, which may reduce the 
half-life of micelles in blood. As a result, PEGylation may 
improve the stability of the drug-loaded micelles and prolong 
circulation in blood.13–15
Previously, the authors developed PEGylated stearic acid-
grafted CS (PEG-CS-SA), which is an amphiphilic block 
copolymer that can self-aggregate into spherical micelles in an 
aqueous medium. Importantly, it was found that PEG-CS-SA 
micelles can be rapidly internalized into tumor cells and over-
come the uptake by macrophage. However, the PEG-CS-SA 
micelles could also be internalizated into normal cells.16
By coupling specific tumor-homing ligands, such as 
antibodies, sugar, folate, or peptides, to the nanoparticles, an 
active targeting of drug to cancer cells with fewer side effects 
was obtained. Solid tumors need new blood vessels to feed 
and nourish them as well as to allow tumor cells to escape 
into the circulation and lodge in other organs, which is termed 
“angiogenesis.”17 Some tumor cells within solid tumors would 
overexpress integrins ανβ3 and ανβ5, which can specifically 
recognize the peptide motif Arg-Gly-Asp (RGD).18 Thus, the 
targeting of RGD-modified micelles to tumor vasculature is 
a promising strategy for tumor-targeting treatment.
Here, by coupling linear RGD to the PEG-CS-SA micelles, 
a novel tumor vasculature-targeting polymeric micelle was 
developed. These micelles were termed “RGD-PEG-CS-SA 
micelles.” The physicochemical properties, such as critical 
micelle concentration (CMC), micelle size, and zeta poten-
tial, were investigated in detail. Doxorubicin (DOX) was 
chosen as a model anticancer drug to investigate the drug 
entrapment efficiency, in vitro drug-release profile, and in 
vitro antitumor activities of drug-loaded RGD-PEG-CS-SA 
micelles in human hepatocellular carcinoma cell line (BEL-
7402) (which overexpress integrins ανβ3 and ανβ5) and 
human epithelial carcinoma cell line (Hela) (integrins ανβ3 
and ανβ5 deficient).
Materials
CS of low molecular weight (Mw = 5.0 kDa) was   prepared by 
enzymatic degradation of CS (95% acetylate, Mw = 450 kDa; 
Yuhuan Marine Biochemistry Co, Ltd,   Zhejiang, China) 
as described in a previous work.19 Stearic acid (SA) was 
purchased from Shanghai Chemical Reagent Co, Ltd, 
(Shanghai, China) and mPEG2000 with aldehyde side group, 
NH2-PEG-NH2, fluorescein isothiocyanate (FITC) and 
3-(4, 5-  dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) were purchased from Sigma-Aldrich Inc, 
(St Louis, MO). N,N′-Disuccinimidyl carbonate (DSC) 
was   purchased from Bio Basic Inc, (Toronto, Canada). 
Di-tert-butyl dicarbonate ((Boc)2O) and 1-ethyl-3-(3-
  dimethylaminopropyl) carbodiimide (EDC) were purchased 
from Shanghai Medpep Co, Ltd, (Shanghai, China). Pyrene 
was purchased from Aldrich Chemical Co, (Milwaukee, WI). 
Doxorubicin hydrochlorate (DOX⋅HCl) was gifted from 
Zhejiang Hisun Pharmaceutical Co, Ltd, (Taizhou   Zhejiang, 
China). Chitosanase was purchased from Dyadic Interna-
tional Inc, (Jupiter, Florida). Trypsin and Dulbecco’s modi-
fied Eagle’s medium were purchased from Gibco-BRL Life 
Technologies (Carlsbad, CA). Fetal bovine serum was pur-
chased from Sijiqing Biology Engineering Materials Co, Ltd, 
(  Zhejiang, China). All other chemicals used were of analytical 
or chromatographic grade.
Methods
Synthesis of SA-grafted CS copolymer 
(CS-SA) and PEGylated CS-SA  
(PEG-CS-SA) copolymers
CS-SA was synthesized by EDC-mediated coupling reac-
tion of amino groups of low-molecular-weight CS and a 
carboxyl group of SA20,21 with some modification. Briefly, 
2.0 g CS was dissolved in 125 mL deionized (DI) water, 
and 0.84 g SA with 5.6 g EDC was dissolved in 100 mL 
anhydrous ethanol, followed by stirring in water bath at 
60°C for 1 hour. The mixture was then added to the CS 
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solution at 80°C under mechanical stirring, and the reaction 
was carried out for 5 hours at 80°C under mechanical stir-
ring at 250 rpm. After the reaction, the reaction solution 
was dialyzed against DI water using a dialysis membrane 
(MWCO 3.5 kDa; Spectrum Laboratories, Laguna Hills, 
CA) for 48 hours to remove byproduct and this was fol-
lowed by freeze drying. Then, the lyophilized powder was 
washed with ethanol three times to remove the unreacted 
SA. Finally, the purified product was lyophilized and stored 
at −20°C until further use.
To obtain PEG-CS-SA, 200 mg CS-SA was dissolved 
in 30 mL DI water. Then 55 mg mPEG2000 with aldehyde 
side group (PEG:CS-SA = 1:1, mol:mol) was added to the 
CS-SA solution. The solution was stirred overnight at room 
temperature and then dialyzed against DI water using a dialy-
sis membrane (MWCO: 7 kDa; Spectrum Laboratories) for 
24 hours. The final product was lyophilized.
Synthesis of RGD-modified PEGylated 
CS-SA (RGD-PEG-CS-SA) copolymers
Briefly, 10 mg of RGD peptide was dissolved in dried 
  dimethyl sulfoxide (DMSO), and 3.1 µL (Boc)2O was added 
into the solution. The reaction was carried out for 24 hours 
at 40°C to protect the amine group of RGD. Then, 19.8 mg 
of EDC and 20.8 mg of NH2-PEG-NH2 were added, followed 
by stirring at 40°C for 24 hours. After that, the reaction solu-
tion was reacted with N,N′-Disuccinimidyl carbonate (DSC, 
NH2-PEG-NH2 : DSC = 1:1, mol:mol) for 12 hours at 40°C 
to obtain succinimidyl t-Boc-RGD-PEG-NH2 solution.
To obtain RGD-PEG-CS-SA, CS-SA was added into the 
reaction solution (CS-SA: succinimidyl t-Boc-RGD-PEG-
NH2 = 1:1, mol:mol) and the reaction was maintained at 
40°C for 24 hours. To remove the protection of (Boc)2O to 
RGD peptide, 12 M hydrochloric acid was added, followed 
by reacting for 2 hours. Then the pH of the reaction solution 
was adjusted to 7.0 using 3 M sodium hydroxide. Finally, the 
reaction solution was dialyzed using a dialysis membrane 
(MWCO 14 kDa; Spectrum Laboratories) against DI water 
for 24 hours, followed by lyophilization.
Preparation of DOX-loaded  
copolymer micelles
DOX base, used for the preparation of DOX-loaded micelles, 
was obtained by the reaction between DOX⋅HCl and double 
mole triethylamine in DMSO for 24 hours.22 DOX-loaded 
micelles were prepared by dialysis method.23 To obtain DOX-
loaded micelles, the DOX DMSO solution (DOX concentration 
was 1 mg/mL) was added dropwise to 5 mL PEG-CS-SA and 
RGD-PEG-CS-SA micelles solution (polymers concentration 
was 2 mg/mL). The solution was then dialyzed using a dialysis 
membrane (MWCO 7.0 kDa;   Spectrum Laboratories). The 
dialyzed solution was then diluted with DI water to 10 mL 
(final concentration of micelles was 1 mg/mL).
Characteristics of PEG-CS-SA,  
RGD-PEG-CS-SA and DOX-loaded 
copolymer micelles (PEG-CS-SA/DOX 
and RGD-PEG-CS-SA/DOX)
CMC
The CMC of PEG-CS-SA and RGD-PEG-CS-SA were 
determined by fluorescence measurement using pyrene as 
a probe.21,24 The fluorescence emission spectra of pyrene 
(6 × 10–7 M) in different concentrations (varying from 1 × 10–3 
to 0.25 mg/mL) of PEG-CS-SA or RGD-PEG-CS-SA solu-
tion were measured using a fluorescence spectrophotometer 
(F-2500, Hitachi Co, Japan), with the excitation wavelength 
set at 334 nm. The slits were set at 10 nm (excitation) and 
2.5 nm (emission). The intensities of I1 and I3 were measured 
at the wavelengths corresponding to the first- and third-
highest energy bands, which were 374 nm and 385 nm, 
respectively. Then the intensity ratio of I1 to I3 (I1/I3) in the 
pyrene emission spectra was calculated.
Determination of micelle size and zeta potential
The micelle size and zeta potential of blank micelles and 
DOX-loaded micelles were measured by dynamic light scat-
tering using a Zetasizer (3000HS; Malvern Instruments Ltd, 
Worcestershire, UK).
Drug encapsulation efficiency and drug loading
The drug encapsulation efficiency and drug loading of DOX-
loaded micelles were measured by the centrifugal-ultrafiltration 
method: 0.4 mL of DOX-loaded micelles was added into 
centrifugal-ultrafiltration tubes (MWCO 3.0 kDa, Microcon 
YM-10; Millipore Co, Billerica, MA), and centrifuged at 
10,000 rpm for 30 minutes. The amount of DOX in ultrafiltrate 
(C) was determined by measuring the fluorescent intensity 
(excitation: 498 nm; emission: 553 nm) using a fluorescence 
spectrophotometer (F-2500; Hitachi Co, Tokyo, Japan). The 
total amount of DOX (C0) was measured after dissolving the 
micelles with DMSO aqueous solution (DMSO:H2O = 9:1, 
v/v) to dissociate the DOX-loaded micelles.
The drug encapsulation efficiency (EE, %) and drug load-
ing (DL, %) of DOX-loaded micelles was then calculated by 
the following equations.
  EE%% =
CC
C
0
0
100
−
×   (1)
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  DL% =
− CC
CC Cm
0
0
100
−+
× %  (2)
where C is the DOX concentration in ultrafiltrate; C0 is the 
DOX concentration in the DOX-loaded micelles solution; and 
Cm is the concentration of copolymer in the DOX-loaded 
micelles solution.
In vitro drug-release behaviors  
of DOX-loaded micelles
In vitro drug-release profiles from DOX-loaded micelles were 
performed by using pH 7.4 phosphate-buffered saline (PBS) 
as dissolution media. One milliliter of DOX-loaded micelles 
solution (DOX concentration 5 µg/mL) was put into a dialysis 
membrane (MWCO 3.5 kDa) and added into a plastic tube 
containing 10 mL of PBS solution. The plastic tube was 
then placed in an incubator shaker (HZ-8812S;   Scientific 
and Educational Equipment Plant, Tai Cang, China), which 
was maintained at 37°C and shaken horizontally at 100 
rpm. At certain time intervals, medium was withdrawn and 
changed with fresh medium. The DOX content was measured 
by   fluorescence spectrophotometer (excitation: 498 nm; 
  emission: 553 nm).
Cell culture
BEL-7402 and Hela cells were obtained from the Cell 
Resource Center (Chinese Academy of Medical Sciences, 
Beijing, China). The cells were cultured in Dulbecco’s 
modified Eagle’s medium at 37°C with 5% CO2 under fully 
humidified conditions. All the mediums were supplemented 
with 10% (v/v) fetal bovine serum and penicillin/strepto-
mycin (100 U ⋅ mL −1, 100 U ⋅ mL−1). Cells were subcultured 
regularly using trypsin/ethylenediaminetetraacetic acid.
In vitro cytotoxicity assay
A comparison of cytotoxicity was performed on the test 
cells with an in vitro proliferation using the MTT method.25 
Briefly, BEL-7402 and Hela cells were plated in 96-well 
plates at a density of 1 × 104 cells/well in 200 µL of complete 
medium and incubated for 24 hours to allow the cells to 
attach. Then the cells were exposed to serial concentrations 
of   DOX-loaded micelles at 37°C for 48 hours. At the end 
of incubation, 20 µL of the MTT   solution was added and 
incubated at 37°C for another 4 hours, and then the media 
was replaced with 100 µL DMSO to dissolve the MTT for-
mazan crystals. Plates were shaken for 10 minutes and the 
absorbance was measured at 570 nm in a microplate reader 
(Model 680; BioRad, Hercules, CA).
In vitro cellular uptake
BEL-7402 and Hela cells were seeded in a 24-well plate 
(Nalge Nunc International, Naperville, IL) and incubated for 
24 hours to allow the cells to attach. A certain amount of free 
DOX⋅HCl and DOX-loaded micelles (DOX concentration 5 
µg/mL) were added, and the cells were further incubated for 
different lengths of time (2 hours, 8 hours, and 24 hours). 
After washing the cells with PBS (pH 7.4) three times, the 
cellular uptake was observed by fluorescence microscope 
(DMIL; Leica Microsystems Ltd, Wetzlar, Germany).
Quantitative analysis of DOX content 
internalized into cells
BEL-7402 and Hela cells were seeded in a 24-well plate (Nalge 
Nunc International) and incubated for 24 hours to allow the cells 
to attach. After the cells were incubated with free DOX⋅HCl 
and DOX-loaded micelles (DOX concentration 5 µg/mL) for 
different lengths of time (2 hours, 4 hours, 6 hours, 10 hours, 
and 24 hours), the medium was removed and the cells were 
rinsed three times with PBS (pH 7.4). Trypsin PBS solution 
(50 µL) with 2.5 mg/mL concentration was then added and 
further incubated for 15 minutes. Then the cells were harvested 
by adding 950 µL DMSO solution followed by sonicate treat-
ment in an ice water bath for 30 minutes to ensure complete 
lysis. After the suspension was centrifuged at 4000 rpm for 
5 minutes, the drug content in the supernatant was measured 
by fluorescence spectrophotometer. The DOX concentration in 
cells was normalized with the protein content in cells, which 
was quantified using a BCA (bicinchoninic acid) protein assay 
kit (Beyotime Institute of Biotechnology, Jiangsu, China).26 
Briefly, the BCA working solution was preprepared by mixing 
the reagent A with reagent B (reagent A: B = 50:1, v/v) for 
further use. Then, 20 μL samples with a series of concentra-
tions were added into 96-well plate, followed by incubated with   
200 μL BCA working solution at 37°C. After 30 minutes, the 
assay was carried out at 570 nm by using a microplate reader 
(Model 680; BioRad, Hercules, CA). Typical standard curve for 
bovine serum albumin were used in the BCA protein assay.
To further investigate the role of RGD peptide in cellular 
uptake, RGD competition studies were performed. Briefly, 
BEL-7402 and Hela cells were pretreated with free RGD 
peptides for 30 minutes, and then incubated with DOX-loaded 
micelles. The cellular uptake percentage was determined as 
described above.
Statistical analysis
Data were expressed as means of the three separate experiments. 
The significances of the differences were determined using 
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Figure 1 Synthetic scheme of RGD-PEG-CS-SA copolymer.
Abbreviations: RGD, Arg-Gly-Asp; PEG, poly(ethylene glycol); SA, stearic acid; 
CS, chitosan; DSC, N,N′-Disuccinimidyl carbonate; HCl, hydrochloric acid.
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Figure  2  Characteristics  of  copolymers  and  blank  micelles.  (A)  Change  of 
fluorescence intensity ratio (I374/I385) for pyrene in distilled water versus the logarithm 
of concentration of copolymers. The unit of concentration was µg/mL. Poly(ethylene 
glycol)-modified stearic acid-grafted chitosan (PEG-CS-SA) (∆); RGD-PEG-CS-SA (□). 
(B) Size distribution of blank RGD-PEG-CS-SA and (C) DOX-loaded RGD-PEG-CS-SA 
micelles obtained by DLS.
Abbreviations: DLS, dynamic light scattering; RGD, Arg-Gly-Asp.
Table 1 Size and zeta potential of blank and DOX-loaded micelles 
with 1 mg/mL concentration
Sample Size 
(nm)
PI 
(−)
Zeta potential 
(mV)
PEG-CS-SA 39.1 ± 1.8 0.52 ± 0.23 29.6 ± 2.5
RGD-PEG-CS-SA 32.4 ± 3.3 0.55 ± 0.14 31.5 ± 2.1
PEG-CS-SA/DOX 21.5 ± 1.0 0.48 ± 0.11 26.0 ± 0.8
RGD-PEG-CS-SA/DOX 24.8 ± 0.6 0.40 ± 0.09 22.7 ± 2.9
Note: PI represents the polydispersity index of the micelle size. Data represent the 
mean ± standard deviation (n = 3).
Abbreviations:  DOX,  doxorubicin;  PEG-CS-SA,  poly(ethylene  glycol)-modified 
stearic acid-grafted chitosan; RGD, Arg-Gly-Asp.
Student’s t-test two-tailed for each paired experiment. A P-value 
,0.05 was considered statistically significant in all cases.
Results and discussion
Synthesis of CS-SA, PEG-CS-SA,  
and RGD-PEG-CS-SA
The CS-SA was synthesized by coupling reaction between 
the amino groups of CS and carboxyl group of SA in the 
presence of water-soluble EDC, and the PEG-CS-SA was 
conducted by the reaction between the remaining amino 
groups of CS-SA and aldehyde group of PEG.
The t-Boc-RGD-PEG-NH2 was prepared by the   chemical 
reaction between RGD (its amino terminus preprotected 
by (Boc)2O) and NH2-PEG-NH2 in the presence of EDC. 
The t-Boc-RGD-PEG-CS-SA was synthesized by con-
jugating the remaining amino groups of NH2-PEG-NH2 
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and the remaining primary amino groups in CS-SA in the 
  presence of DSC. Figure 1 presents the synthesis scheme of 
  RGD-PEG-CS-SA.
Characteristics of PEG-CS-SA,  
RGD-PEG-CS-SA and DOX-loaded 
micelles
The CMC can indicate the self-aggregation ability of the 
amphiphilic copolymers. Figure 2 shows the change in the 
value of I1/I3 against the logarithm of PEG-CS-SA or RGD-
PEG-CS-SA concentration. When in the lower polymer 
concentration, the value of I1/I3 stayed almost constant. 
Once the polymer concentration reached above the CMC, 
the value of I1/I3 reduced sharply, indicating the formation of 
micelles.27 There was no significant difference in the CMC 
values of two kinds of copolymers, and the CMC values 
of PEG-CS-SA and RGD-PEG-CS-SA were determined 
to be 25.9 ± 1.2 µg/mL and 23.5 ± 0.5 µg/mL in DI water, 
respectively. The CMC values were much lower than those of 
low-molecular-weight surfactants in water, showing that they 
can easily self-aggregate to form micelles in DI water.
The particle size and surface zeta potential of blank and 
DOX-loaded micelles (1 mg/mL in DI water) are shown in 
Table 1. Figure 2B and C show the size distribution of blank 
RGD-PEG-CS-SA and DOX-loaded RGD-PEG-CS-SA 
micelles, which were obtained by dynamic light scattering   
determination, suggesting that the micelles had a narrow 
size distribution.
The size and distribution of micelles may play important 
roles in transport in vivo. Micelles with smaller size tended 
to accumulate easily in tumor sites due to the EPR effect, 
and gained faster internalization into cells.28,29 The results 
showed that the sizes of DOX-loaded micelles were smaller 
than those of blank micelles, which may benefit from hydro-
phobic interaction between poorly water-soluble drug and 
the hydrophobic cores of polymeric micelles. It was also 
found that the zeta potentials were reduced after the loading 
of drug, which may be because the change of the size and 
surface charge density.
The drug encapsulation efficiency and drug loading of 
DOX-loaded PEG-CS-SA and RGD-PEG-CS-SA micelles 
are shown in Table 2. The results indicate that there was 
no significant difference in the encapsulation efficiency of 
micelles after further modification by RGD peptide, sug-
gesting that modification of RGD peptide did not affect the 
drug-entrapment ability of PEG-CS-SA micelles.
In vitro drug-release behaviors
In vitro DOX release profiles of DOX-loaded PEG-CS-SA 
and RGD-PEG-CS-SA micelles in pH 7.4 PBS are shown 
in   Figure 3. The in vitro release of DOX from DOX-loaded 
micelles could be prolonged for 9 days, and almost 35% of 
DOX was released during 48 hours. As shown in Figure 3, 
the release rate of DOX from RGD-PEG-CS-SA micelles 
Table  2  Drug-loading  capacity  and  encapsulation  efficiency 
of PEG-CS-SA and RGD-PEG-CS-SA micelles loading DOX
Sample Drug loading  
capacity 
(%)
Encapsulation   
efficiency 
(%)
PEG-CS-SA /DOX 4.9 ± 0.3 95.8 ± 3.4
RGD-PEG-CS-SA /DOX 4.6 ± 0.5 93.2 ± 3.3
Note: Data represent the mean ± standard deviation (n = 3).
Abbreviations:  DOX,  doxorubicin;  PEG-CS-SA,  poly(ethylene  glycol)-modified 
stearic acid-grafted chitosan; RGD, Arg-Gly-Asp.
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Figure 3 In vitro doxorubicin (DOX)-release profiles from poly(ethylene glycol)-modified stearic acid-grafted chitosan (PEG-CS-SA)/DOX (◊) and RGD-PEG-CS-SA/DOX (∆) 
micelles using pH 7.4 phosphate-buffered saline.
Note: Data represent the mean ± standard deviation (n = 3).
Abbreviation: RGD, Arg-Gly-Asp.
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decreased significantly as compared with PEG-CS-SA/DOX 
micelles. These results indicate that RGD-PEG-CS-SA micelles 
could be employed as a drug carrier for retarding DOX release, 
which is helpful for decreasing drug leakage from carriers 
before drug-loaded carriers arrive at the target cells.
In vitro cytotoxicity assay
The cytotoxicity of blank and DOX-loaded micelles against 
BEL-7402 and Hela cells was evaluated using the MTT test. 
The variation of cell viability against the drug concentration 
of DOX⋅HCl solution and DOX-loaded micelles is shown in 
Figure 4.
The IC50 values of PEG-CS-SA and RGD-PEG-CS-SA 
micelles against BEL-7402 and Hela cells were determined and 
these ranged from 331.2 ± 1.8 µg/mL to 490.5 ± 2.9 µg/mL, 
indicating that the micelles were low-toxicity carriers for 
cancer therapy, compared with other cationic polymers like 
polyethylenimine and its derivatives.30
The in vitro cytotoxicities of DOX-loaded micelles were 
evaluated and compared with free DOX⋅HCl. It was found that 
the antitumor activities were significantly increased when DOX 
was loaded into micelles, and the antitumor activities against 
BEL-7402 cells (which overexpress integrins ανβ3 and ανβ5) 
were further increased after the modification of   PEG-CS-SA 
micelles with RGD peptide (by 7.2 fold, P , 0.05). The 
enhanced cytotoxicities of DOX-loaded micelles, especially 
RGD-modified DOX-loaded micelles, were due to the faster 
internalization of DOX into cells mediated by the micelles 
and integrin-mediated endocytosis. Moreover, the modifica-
tion of DOX-loaded PEG-CS-SA micelles by RGD peptide 
would not affect the cytotoxicity of micelles against Hela cells, 
which did not overexpress integrins ανβ3 and ανβ5.
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Figure 4 Cytotoxicity of DOX ⋅ HCl, poly(ethylene glycol)-modified stearic acid-grafted chitosan (PEG-CS-SA)/DOX and RGD-PEG-CS-SA/DOX toward (A) human 
hepatocellular carcinoma cell line cells and (B) human epithelial carcinoma cell line cells.
Note: Data represent the mean ± standard deviation (n = 3).
Abbreviations: DOX, doxorubicin; HCl, hydrochloric acid; RGD, Arg-Gly-Asp.
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Figure 5 Fluorescence images of doxorubicin (DOX) after (A) human hepatocellular 
carcinoma cell line cells and (B) human epithelial carcinoma cell line cells were 
incubated with free DOX, poly(ethylene glycol)-modified stearic acid-grafted chitosan 
(PEG-CS-SA)/DOX and RGD-PEG-CS-SA/DOX micelles for 2 hours, 8 hours, and 
24 hours, respectively.
Abbreviation: RGD, Arg-Gly-Asp.
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In vitro cellular uptake
Using BEL-7402 and Hela cells as model tumor cells, the in 
vitro cellular uptakes of DOX-loaded micelles were   carried out. 
The cellular uptake was observed by fluorescence microscope 
after the cells were incubated with free DOX⋅HCl, DOX-loaded 
PEG-CS-SA, and RGD-PEG-CS-SA micelles solution for 
different incubation times. Figure 5 shows the fluorescence 
images of DOX against BEL-7402 and Hela cells with incuba-
tion times of 2 hours, 8 hours, and 24 hours, respectively.
It was clear that the DOX fluorescence intensities were 
increased with the incubation time, which demonstrated that 
cellular uptakes of free DOX⋅HCl, DOX-loaded PEG-CS-SA, 
and RGD-PEG-CS-SA micelles were time dependent. At 
the same incubation time, the DOX fluorescence intensity 
in BEL-7402 and Hela cells was enhanced when DOX was 
loaded into micelles. Furthermore, the cellular uptakes of 
DOX in BEL-7402 cells were further enhanced after the 
modification of PEG-CS-SA micelles with RGD peptide, 
while not in Hela cells.
The RGD-modified micelles displayed much faster and 
more cellular uptake for BEL-7402 cells, which may be due 
to the specific binding of RGD-modified micelles to BEL-
7402 cells and internalization into cells by integrin-mediated 
endocytosis.
Quantitative analysis of DOX  
content internalized into cells
To further confirm whether RGD-modified DOX-loaded 
micelles could be specifically internalized into BEL-
7402 cells, the DOX contents internalized into cells were 
quantitatively evaluated. To further investigate the role of 
RGD peptide in the cellular uptake of RGD-PEG-CS-SA 
micelles, BEL-7402 cells were pretreated with free RGD 
peptide for 30 minutes to saturate the overexpressing integrins 
and then incubated with free DOX⋅HCl and DOX-loaded 
micelles. Cellular uptake kinetics of micelles were examined 
for BEL-7402 and Hela cells at elapsed time points, shown 
in Figure 6.
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Figure 6 Cellular uptake percentage of free DOX, DOX-loaded micelles in (A) human hepatocellular carcinoma cell line cells and (B) human epithelial carcinoma cell line 
cells against incubation time.
Notes: Data represent the mean ± standard deviation (n = 3). *P . 0.05 and **P , 0.01.
Abbreviations: DOX, doxorubicin; PEG-CS-SA, poly(ethylene glycol)-modified stearic acid-grafted chitosan; RGD, Arg-Gly-Asp.
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As expected, the quantitative uptakes were in accordance 
with the qualitative uptakes, thus confirming again that the 
role of integrin-mediated process in the cellular uptake of 
RGD-PEG-CS-SA micelles in BEL-7402 cells. Moreover, 
the cellular uptake of RGD-PEG-CS-SA micelles by BEL-
7402 cells was obviously inhibited after the cells were pre-
treated by excess free RGD peptide. It indicated that excess 
free RGD peptide inhibited the cell binding and uptake of the 
RGD-PEG-CS-SA micelles by competitive binding to inte-
grin on the surface of BEL-7402 cells. Overall, these results 
show that integrin is responsible for the specific binding and 
uptake of RGD-modified micelles, and the cell uptake is a 
receptor-mediated process.
Conclusion
RGD-modified micelles were successfully synthesized and 
prepared by self-aggregation from copolymer in the aque-
ous medium with a lower CMC value of 23.5 ± 0.5 µg/mL. 
The cellular uptake of RGD-PEG-CS-SA micelles was 
significantly enhanced in the integrins overexpressed cell 
lines (BEL-7402), compared with the integrins deficient 
cell lines (Hela). Moreover, the cytotoxicity of DOX-loaded 
RGD-PEG-CS-SA micelles was improved sharply by 7.2-fold 
(P , 0.05) compared to free DOX.HCl, contributing to 
the increased intracellular delivery of the drug. The RGD-
modified polymeric micelles that are presented may be a 
promising active-targeting drug carrier for tumor therapy 
via integrin mediation.
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